Sondergaard B C, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Bräuer R, Danielsen I, Christiansen C, Qvist P, Karsdal M A
Nordic Bioscience Diagnostics, Herlev, Denmark.
Osteoarthritis Cartilage. 2006 Aug;14(8):738-48. doi: 10.1016/j.joca.2006.01.016. Epub 2006 Mar 23.
Both matrix metalloprotease (MMP) activity and cathepsin K (CK) activity have been implicated in cartilage turnover. We investigated the relative contribution of MMP activity and CK activity in cartilage degradation using ex vivo and in vivo models.
Bovine articular cartilage explants were stimulated with oncostatin M (OSM) 10 ng/ml and tumor necrosis factor-alpha (TNF-alpha) 20 ng/ml in the presence or absence of the broad-spectrum MMP inhibitor GM6001 and the cysteine protease inhibitor, E64. Cartilage degradation was evaluated in the conditioned medium by glycosaminoglycans (GAG), hydroxyproline, and cross-linked C-telopeptide fragments of type II collagen (CTX-II), which were compared to immunohistochemical evaluations of proteoglycans and CTX-II. We assessed MMP expression by gelatine zymography and CK expression by immunohistochemistry. In vivo, CTX-II release was measured from CK-deficient mice.
OSM and TNF-alpha combined induced significant (P<0.01) increase in cartilage degradation products measured by hydroxyproline and CTX-II compared to vehicle control. The cytokines potently induced MMP expression, assessed by zymography, and CK expression investigated by immunohistochemistry. Inhibition of MMP activity completely abrogated hydroxyproline and CTX-II release (P<0.01) and GAG release (P<0.05). In contrast, E64 resulted in increased CTX-II release by 100% (P<0.05) and inhibited GAG release by 30%. Up-regulation of CTX-II fragments was confirmed in vivo in CK null mice.
Inhibition of MMP activity reduced both proteoglycan loss and type II collagen degradation. In contrast, inhibition of cysteine proteases resulted in an increase rather than a decrease in MMP derived fragments of collagen type II degradation, CTX-II, suggesting altered collagen metabolism.
基质金属蛋白酶(MMP)活性和组织蛋白酶K(CK)活性均与软骨周转有关。我们使用体外和体内模型研究了MMP活性和CK活性在软骨降解中的相对作用。
在存在或不存在广谱MMP抑制剂GM6001和半胱氨酸蛋白酶抑制剂E64的情况下,用10 ng/ml制瘤素M(OSM)和20 ng/ml肿瘤坏死因子-α(TNF-α)刺激牛关节软骨外植体。通过糖胺聚糖(GAG)、羟脯氨酸和II型胶原交联C-末端肽片段(CTX-II)在条件培养基中评估软骨降解情况,并与蛋白聚糖和CTX-II的免疫组织化学评估结果进行比较。通过明胶酶谱法评估MMP表达,通过免疫组织化学评估CK表达。在体内,测量CK缺陷小鼠的CTX-II释放量。
与载体对照相比,OSM和TNF-α联合诱导羟脯氨酸和CTX-II测量的软骨降解产物显著增加(P<0.01)。细胞因子强烈诱导通过酶谱法评估的MMP表达和通过免疫组织化学研究的CK表达。抑制MMP活性完全消除了羟脯氨酸和CTX-II释放(P<0.01)以及GAG释放(P<0.05)。相比之下,E64导致CTX-II释放增加100%(P<0.05),并抑制GAG释放30%。在CK基因敲除小鼠体内证实了CTX-II片段上调。
抑制MMP活性可减少蛋白聚糖损失和II型胶原降解。相比之下,抑制半胱氨酸蛋白酶导致II型胶原降解的MMP衍生片段CTX-II增加而非减少,提示胶原代谢改变。